Fulgent Genetics Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts
Shares of Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) have been assigned an average recommendation of "Hold" from the five analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company.
Fulgent Genetics: A Major Market Misconception
Fulgent Genetics' Q4 2025 earnings report caused a massive share price decline of roughly 40%. The sell off has exacerbated the market's misconception about FLGT that already existed before the earnings were released. An investor can use these new depressed prices to protect their downside while waiting patiently for a change in the company's fortunes to rerate shares dramatically to the upside.
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock
Fulgent Genetics offers a fortress balance sheet, zero debt, and net assets near the current share price, providing downside protection. FLGT's diagnostics business is growing, with 15.4% revenue growth YTD and all segments contributing, notably BioPharma services up 72%. Management is highly aligned, owning 33% of shares, executing opportunistic buybacks, and prioritizing disciplined M&A for further growth.
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.
